.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Chinese Patent Office
Medtronic
Covington
Queensland Health
Cerilliant
Novartis
Mallinckrodt
US Department of Justice
Daiichi Sankyo

Generated: September 19, 2017

Patent: ► Subscribe

Summary for Patent: ► Subscribe

Title:Combination therapy using anti-EGFR and anti-HER2 antibodies
Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody \"trastuzumab\" (HERCEPTIN.RTM.) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody \"matuzumab\" (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.
Inventor(s): Gillies; Stephen D. (Carlisle, MA), Azria; David (Mauguio, FR), Larbouret; Christel (Montpellier, FR), Pelegrin; Andre (Montpellier, FR)
Assignee: L\'Institut National de la Sante et de la Recherche Medicale (Paris, FR)
Application Number:14/536,854
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe L\'Institut National de la Sante et de la Recherche Medicale (Paris, FR) Gillies; Stephen D. (Carlisle, MA), Azria; David (Mauguio, FR), Larbouret; Christel (Montpellier, FR), Pelegrin; Andre (Montpellier, FR) ► SubscribeRXOrphansearch
Imclone
ERBITUX
cetuximab
VIAL; INTRAVENOUS1250840012004-06-18► Subscribe L\'Institut National de la Sante et de la Recherche Medicale (Paris, FR) Gillies; Stephen D. (Carlisle, MA), Azria; David (Mauguio, FR), Larbouret; Christel (Montpellier, FR), Pelegrin; Andre (Montpellier, FR) ► SubscribeRXOrphansearch
Amgen
VECTIBIX
panitumumab
INJECTABLE; IV (INFUSION)1251470012006-09-27► Subscribe L\'Institut National de la Sante et de la Recherche Medicale (Paris, FR) Gillies; Stephen D. (Carlisle, MA), Azria; David (Mauguio, FR), Larbouret; Christel (Montpellier, FR), Pelegrin; Andre (Montpellier, FR) ► SubscribeRXsearch
Amgen
VECTIBIX
panitumumab
INJECTABLE; IV (INFUSION)1251470022006-09-27► Subscribe L\'Institut National de la Sante et de la Recherche Medicale (Paris, FR) Gillies; Stephen D. (Carlisle, MA), Azria; David (Mauguio, FR), Larbouret; Christel (Montpellier, FR), Pelegrin; Andre (Montpellier, FR) ► SubscribeRXsearch
Amgen
VECTIBIX
panitumumab
INJECTABLE; IV (INFUSION)1251470032006-09-27► Subscribe L\'Institut National de la Sante et de la Recherche Medicale (Paris, FR) Gillies; Stephen D. (Carlisle, MA), Azria; David (Mauguio, FR), Larbouret; Christel (Montpellier, FR), Pelegrin; Andre (Montpellier, FR) ► SubscribeRXsearch
Genentech
PERJETA
pertuzumab
VIAL; SINGLE-USE1254090012012-06-08► Subscribe L\'Institut National de la Sante et de la Recherche Medicale (Paris, FR) Gillies; Stephen D. (Carlisle, MA), Azria; David (Mauguio, FR), Larbouret; Christel (Montpellier, FR), Pelegrin; Andre (Montpellier, FR) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Summary for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06000107Jan 4, 2006

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Argentina059127Mar 12, 2008
Australia2006332212Jul 12, 2007
Australia2006332212Mar 28, 2013
Australia2006332212May 30, 2013
BrazilPI0620888Nov 29, 2011
Canada2636074Jul 12, 2007
China101365486Feb 11, 2009
China101365486Oct 31, 2012
Eurasian Patent Organization015173Jun 30, 2011
Eurasian Patent Organization200870141Feb 27, 2009
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Citi
Colorcon
Deloitte
Fuji
Julphar
AstraZeneca
Mallinckrodt
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot